Antigen presentation of detergent-free glutamate decarboxylase (GAD65) is affected by human serum albumin as carrier protein

Journal of Immunological Methods

Volumn 334, Issue 1-2, 2008, Pages 114-121

  Steed, Jordan ^a   Gilliam, Lisa K ^a   Harris, Robert A ^b   Lernmark, Åke ^a   Hampe, Christiane S ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antigen presentation processing; T cell assay; Type 1 diabetes

Indexed keywords

DETERGENT; GLUTAMATE DECARBOXYLASE 65; GLUTAMATE DECARBOXYLASE 65 ANTIBODY; HLA DR ANTIGEN; HUMAN SERUM ALBUMIN;

ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ARTICLE; BINDING COMPETITION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HYBRIDOMA; PRIORITY JOURNAL; T LYMPHOCYTE;

ANTIGEN PRESENTATION; B-LYMPHOCYTES; CELL LINE; GLUTAMATE DECARBOXYLASE; HUMANS; HYBRIDOMAS; INTERLEUKIN-2; RADIOLIGAND ASSAY; RECOMBINANT PROTEINS; SERUM ALBUMIN; T-LYMPHOCYTES;

EID: 41949090941     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jim.2008.02.006     Document Type: Article

References (35)

1. Agardh C.D., Cilio C.M., Lethagen A., Lynch K., Leslie R.D., Palmer M., Harris R.A., Robertson J.A., and Lernmark A. Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. J. Diabetes Complicat. 19 (2005) 238
2. Bingley P.J., Bonifacio E., and Mueller P.W. Diabetes Antibody Standardization Program: first assay proficiency evaluation. Diabetes 52 (2003) 1128
3. Christgau S., Schierbeck H., Aanstoot H.-J., Aagaard L., Begley K., Kofod H., Hejnaes K., and Baekkeskov S. Pancreatic ß cells express two autoantigenic forms of glutamic acid decarboxylase, a 65-kDa hydrophilic form and a 64-kDa amphiphilic form which can be both membrane-bound and soluble. J. Biol. Chem. 286 (1991) 21257
4. 2-terminal domain. J. Cell Biol. 118 (1992) 309
5. 2-terminal region of the 65-kDa isoform of glutamic acid decarboxylase. J. Biol. Chem. 270 (1995) 2241
6. Falorni A., Örtqvist E., Persson B., and Lernmark Å. Radioimmunoassays for glutamic acid decarboxylase (GAD65) and GAD65 autoantibodies using 35S or 3H recombinant human ligands. J. Immunol. Methods 186 (1995) 89
7. Falorni A., Ackefors M., Carlberg C., Daniels T., Persson B., Robertson J., and Lernmark A. Diagnostic sensitivity of immunodominant epitopes of glutamic acid decarboxylase (GAD65) autoantibodies in childhood IDDM. Diabetologia 39 (1996) 1091
8. Fasano M., Curry S., Terreno E., Galliano M., Fanali G., Narciso P., Notari S., and Ascenzi P. The extraordinary ligand binding properties of human serum albumin. IUBMB Life 57 (2005) 787
9. Fenalti G., Law R.H., Buckle A.M., Langendorf C., Tuck K., Rosado C.J., Faux N.G., Mahmood K., Hampe C.S., Banga J.P., Wilce M., Schmidberger J., Rossjohn J., El-Kabbani O., Pike R.N., Smith A.I., Mackay I.R., Rowley M.J., and Whisstock J.C. GABA production by glutamic acid decarboxylase is regulated by a dynamic catalytic loop. Nat. Struct. Mol. Biol. 14 (2007) 280
10. Gottlieb D.I., Chang Y.-C., and Schwob J.E. Monoclonal antibodies to glutamic acid decarboxylase. Proc. Natl. Acad. Sci. 83 (1986) 8808
11. Grubin C., Daniels T., Karlsen A.E., Boel E., Hagopian W.A., and Lernmark Å. The cDNA-directed, in vitro-synthesized nascent peptide of glutamic acid decarboxylase (GAD2) is the autoantigen in insulin-dependent diabetes. Clin. Res. 40 (1992) 299A
12. Grubin C.E., Daniels T., Toivola B., Landin-Olsson M., Hagopian W.A., Li L., Karlsen A.E., Boel E., Michelsen B., and Lernmark Å. A novel radioligand binding assay to determine diagnostic accuracy of isoform-specific glutamic acid decarboxylase antibodies in childhood IDDM. Diabetologia 37 (1994) 344
13. Hampe C.S., Hammerle L.P., Bekris L., Ortqvist E., Kockum I., Rolandsson O., Landin-Olsson M., Torn C., Persson B., and Lernmark A. Recognition of glutamic acid decarboxylase (GAD) by autoantibodies from different GAD antibody-positive phenotypes. J. Clin. Endocrinol. Metab. 85 (2000) 4671
14. Hampe C.S., Lundgren P., T.L., D., Hammerle L.P., Marcovina S.M., and Lernmark Å. A novel monoclonal antibody specific for the N-terminal end of GAD65. J. Neuroimmunol. 113 (2001) 63
15. Jacquier-Sarlin M.R., Gabert F.M., Villiers M.B., and Colomb M.G. Modulation of antigen processing and presentation by covalently linked complement C3b fragment. Immunology 84 (1995) 164
16. Kanaani J., el-Husseini Ael D., Aguilera-Moreno A., Diacovo J.M., Bredt D.S., and Baekkeskov S. A combination of three distinct trafficking signals mediates axonal targeting and presynaptic clustering of GAD65. J. Cell Biol. 158 (2002) 1229
17. 2-terminal epitope in the autoantigen GAD65, distinguish Stiff-Man syndrome from insulin-dependent diabetes mellitus. J. Exp. Med. 180 (1994) 595
18. Kragh-Hansen U. Structure and ligand binding properties of human serum albumin. Dan. Med. Bull. 37 (1990) 57
19. Lernmark A. Controlling the controls: GAD65 autoreactive T cells in type 1 diabetes. J. Clin. Invest. 109 (2002) 869
20. Liu E., and Eisenbarth G.S. Type 1A diabetes mellitus-associated autoimmunity. Endocrinol. Metab. Clin. N. Am. 31 (2002) 391 (vii-viii)
21. Ludvigsson J., Heding L., Liedén G., Marner B., and Lernmark Å. Plasmapheresis in the initial treatment of insulin-dependent diabetes mellitus in children. Br. Med. J. 286 (1983) 176
22. Marner B., Lernmark Å., Ludvigsson J., MacKay P., Matsuba I., Nerup J., and Rabinovitch A. Islet cell antibodies in insulin-dependent (Type 1) diabetic children treated with plasmapheresis. Diabetes Res. 2 (1985) 231
23. Martin S.B., Waniewski R.A., Battaglioli G., and Martin D.L. Post-mortem degradation of brain glutamate decarboxylase. Neurochem. Int. 42 (2003) 549
24. Mire-Sluis A.R., Das R.G., and Lernmark Å. The World Health Organization international collaborative study for islet cell antibodies. Diabetologia 43 (2000) 1282
25. Nepom G.T., Lippolis J.D., White F.M., Masewicz S., Marto J.A., Herman A., Luckey C.J., Falk B., Shabanowitz J., Hunt D.F., Engelhard V.H., and Nepom B.S. Identification and modulation of a naturally processed T cell epitope from the diabetes-associated autoantigen human glutamic acid decarboxylase 65 (hGAD65). Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 1763
26. Peakman M., Tree T.I., Endl J., van Endert P., Atkinson M.A., and Roep B.O. Characterization of preparations of GAD65, proinsulin, and the islet tyrosine phosphatase IA-2 for use in detection of autoreactive T-cells in type 1 diabetes: report of phase II of the Second International Immunology of Diabetes Society Workshop for Standardization of T-cell assays in type 1 diabetes. Diabetes 50 (2001) 1749
27. Pihoker C., Gilliam L.K., Hampe C.S., and Lernmark A. Autoantibodies in diabetes. Diabetes 54 Suppl 2 (2005) S52
28. *0401-positive individuals. J. Immunol. 163 (1999) 1674
29. Roep B.O., Atkinson M.A., van Endert P.M., Gottlieb P.A., Wilson S.B., and Sachs J.A. Autoreactive T cell responses in insulin-dependent (type 1) diabetes mellitus. Report of the first international workshop for standardization of T cell assays. J. Autoimmun. 13 (1999) 267
30. Simitsek P.D., Campbell D.G., Lanzavecchia A., Fairweather N., and Watts C. Modulation of antigen processing by bound antibodies can boost or suppress class II major histocompatibility complex presentation of different T cell determinants. J. Exp. Med. 181 (1995) 1957
31. Solimena M., Dirkx Jr. R., Radzynski M., Mudigl O., and De Camilli P. A signal located within amino acids 1-27 of GAD65 is required for its targeting to the Golgi complex region. J. Cell Biol. 126 (1994) 331
32. Watts C. Suppressive effect of antibody on processing of T cell epitopes. J. Exp. Med. 178 (1993) 1459
33. *0401. J. Clin. Invest. 98 (1996) 2597
34. Yoon J.W., Jun H.S., and Santamaria P. Cellular and molecular mechanisms for the initiation and progression of beta cell destruction resulting from the collaboration between macrophages and T cells. Autoimmunity 27 (1998) 109
35. Zhong D., Douhal A., and Zewail A.H. Femtosecond studies of protein-ligand hydrophobic binding and dynamics: human serum albumin. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 14056